A Critique View On Skytrofa

Authors

  • Sidda Sravanthi Student, Department of Pharmacy, Joginpally B. R. Pharmacy College, Hyderabad, India
  • M. Meena Kumari Assistant Professor, Department of Pharmacology, Joginpally B. R. Pharmacy College, Hyderabad, India
  • J. V. C. Sharma Principal, Department of Pharmacognosy,, Joginpally B. R. Pharmacy College, Hyderabad, India

Keywords:

Growth hormone deficiency, Idiopathic short stature, Lonapegsomatropin-tcgd (Tetrahymena comparative genomics database), Noonan syndrome, prepubertal, skytrofa, somatropin, Turner syndrome

Abstract

The aim of this article is to bring awareness about skytrofa a branded drug which is used for children with Growth Hormone Deficiency (GHD). Auto injector is mostly focused on pediatric patients who are at least 1year of age and who are experiencing growth failure caused by an inadequate secretion of endogenous growth hormone. It is based on assessed the safety and efficacy of skytrofa. Skytrofa (lonapegsomatropin-tcgd) is also known as Trans Con hGH or ACP011.Lonapegsomatropin is a long acting, once-weekly prodrug for the treatment of Growth Hormone Deficiency. This review concludes that GHD this is not only important for weight and height but also for endocrine health and development.

Downloads

Download data is not yet available.

Downloads

Published

05-12-2021

Issue

Vol. 4 No. 11 (2021)

Section

Articles

License

Copyright (c) 2021 Sidda Sravanthi, M. Meena Kumari, J. V. C. Sharma

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
S. Sravanthi, M. M. Kumari, and J. V. C. Sharma, “A Critique View On Skytrofa”, IJRESM, vol. 4, no. 11, pp. 188–191, Dec. 2021, Accessed: Apr. 25, 2024. [Online]. Available: https://journal.ijresm.com/index.php/ijresm/article/view/1569

Most read articles by the same author(s)